Homepage Top Section1

FDA has provided the breakthrough therapy status based on data from the BPDCN cohort of the first-in-human study of IMGN632, said ImmunoGen. IMGN632 is a CD123-targeting ADC, which

The deal is valued at around $647m on an enterprise basis, including debt obligations expected to be assumed or repaid net of cash. As per terms of the

Koligo is involved in the development of personalised cell therapies using the cells of the patient. The company already commercialised its first commercial product Kyslecel for the treatment

The company’s investigational new drug application (IND) for the clinical trial will be on partial clinical hold until the regulator receives satisfying answers for the questions. The partial

The scope of the deal comprises technical transfer, and fill and finish manufacture of J&J’s SARS-CoV-2 vaccine candidate. GRAM stated that it is having modern equipment to manufacture

The late-stage trial called ENSEMBLE to be held in multiple countries across three countries will study the safety and efficacy of a single dosage of JNJ-78436735 in comparison

The companies are seeking approval for the use of ide-cel in adult patients with the disease who have been subjected to least three prior therapies. The investigational cell

As part of the partnership, RDIF will supply 100 million doses of the vaccine to Dr. Reddy’s, after securing regulatory approval in India. Developed by the Gamaleya National

Dupixent, a fully-human monoclonal antibody, blocks the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. The regulator has provided breakthrough therapy device designation based on data from